Business context and reporting period
Filing identity discrepancy: The supplied filing is Catalyst Biosciences, Inc. (NASDAQ: CBIO), not GYRE Therapeutics, Inc. It is a Form 10-Q for the quarter ended September 30, 2021, filed November 12, 2021. The summary below reflects the filing provided.
Catalyst was a clinical-stage biopharmaceutical company developing engineered protease therapies, with programs in complement regulation and hemophilia. It had no approved products and no revenue from product sales. The financial statements are unaudited and cover the three and nine months ended September 30, 2021.
Financial performance and condition
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| License and collaboration revenue | $2.3 million | $0.9 million | $4.9 million | $18.9 million |
| Research and development expense | $20.4 million | $12.2 million | $52.8 million | $38.4 million |
| General and administrative expense | $4.9 million | $3.8 million | $14.8 million | $11.9 million |
| Operating loss | $25.2 million | $16.1 million | $67.6 million | $38.5 million |
| Net loss | $25.2 million | $16.0 million | $67.6 million | $37.3 million |
| Net loss per share | $0.80 | $0.73 | $2.23 | $2.05 |
Amounts are rounded. Collaboration revenue largely represented reimbursed Biogen research-service costs, which were nearly matched by collaboration costs. The company reported no product-sale revenue; a conventional product gross margin is therefore not meaningful.
- Cash and investments: $64.5 million at September 30, 2021, comprising $59.2 million cash and cash equivalents and $5.4 million short-term investments. Total was down from $81.9 million in cash and investments at December 31, 2020.
- Cash flow: Operating activities used $66.1 million in the first nine months, versus $32.9 million in the comparable 2020 period. Financing provided $49.6 million, including $49.3 million net proceeds from a first-quarter stock offering; investing provided $45.3 million, primarily from investment maturities.
- Liquidity: Current assets were $74.0 million and current liabilities $17.3 million at quarter-end. Management believed available cash, cash equivalents and investments would fund requirements for at least 12 months from the filing date, based on current plans and assumptions.
- Debt and other obligations: The filing reports no borrowings or debt balance. Total liabilities were $17.8 million, including $2.4 million of operating lease liabilities. The company disclosed manufacturing and clinical-study commitments, including $3.6 million remaining under firm AGC work orders.
Material changes versus prior comparable periods
- Q3 revenue increased 157% year over year, but nine-month revenue fell 74%, principally because the prior-year period included a $15.0 million Biogen upfront license payment that was recognized in 2020.
- Q3 research and development expense rose 66%; nine-month expense rose 37%, driven mainly by higher clinical manufacturing and preclinical research costs. General and administrative expense increased 27% in Q3 and 24% year to date.
- Nine-month net loss increased to $67.6 million from $37.3 million, while operating cash use roughly doubled to $66.1 million.
- Shares issued and outstanding increased to 31.4 million at September 30, 2021 from 22.1 million at December 31, 2020, following the 9.185 million-share offering and other share issuances.
Outlook, commentary, risks and unusual items
- Management expected continued losses and significant expenses for several years, with research and development spending expected to increase as programs advanced. Future financing may be needed; equity financing could dilute shareholders, while debt or partnering could restrict operations or require relinquishing rights.
- On November 11, 2021, after quarter-end, Catalyst announced it would stop clinical development of MarzAA and focus on complement programs and its protease platform. It also discontinued the related MarzAA trials, citing enrollment challenges, competition, COVID-19 delays, and the capital required. The company planned to explore licensing or sale options for MarzAA and DalcA.
- The restructuring was expected to cost approximately $0.6 million, with cash payments of about $0.4 million in Q4 2021 and $0.2 million in Q1 2022. The filing noted that additional charges could arise. It also reported a workforce reduction of approximately 35% of prior headcount.
- Before the strategic shift, the company planned to initiate a Phase 1 CB 4332 study in 2022. Screening and natural-history studies had begun, but the target population is rare and remained uncertain. CB 4332 and other complement candidates faced clinical, regulatory, manufacturing, enrollment and funding risks.
- Biogen collaboration economics included potential development and sales milestones of up to $340 million and future royalties, but timing and receipt were uncertain; Biogen could terminate the agreement on 60 days’ notice.
- In October 2021, the company established an at-the-market equity program for up to $50 million in gross proceeds, with a 3% sales commission. COVID-19 remained a potential source of trial, supply-chain and operating disruption.
- Management reported disclosure controls were effective as of September 30, 2021. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is Catalyst Biosciences (CBIO), not GYRE Therapeutics.
- Review the post-quarter MarzAA discontinuation and restructuring disclosures, including potential additional costs and plans for the hemophilia assets.
- Assess cash runway against the $66.1 million nine-month operating cash outflow, the company’s stated 12-month estimate, and planned complement-program spending.
- Check any subsequent ATM share sales and related dilution; the filing authorizes up to $50 million of gross sales.
- Track CB 4332 study readiness, patient identification and enrollment, and manufacturing progress, along with Biogen program milestones and any future collaboration revenue.